Personalized Therapy With Dalcetrapib Improves Outcomes for Cardiovascular Disease

A new personalized therapy with dalcetrapib for cardiovascular disease has been demonstrated by researchers at the Montreal Heart Institute.

The research team analyzed 5749 patients who received dalcetrapib or placebo and provided DNA in a clinical study. They found a strong association between the effects of dalcetrapib and a specific gene called ADCY9 (adenylate cyclase 9) on chromosome 16, particularly for a specific genetic variant (rs1967309).

In patients with the genetic profile AA at rs1967309, there was a 39 percent reduction in combined clinical outcomes including heart attacks, strokes, unstable angina, coronary revascularizations and cardiovascular deaths with dalcetrapib compared to placebo. From a second study it was seen that patients with the favorable genetic profile also benefited from reduction in the amount of atherosclerosis (thickened walls) of their carotid artery walls with dalcetrapib.

Lead investigator Jean-Claude Tardif said, "These results will lead to a genetics-guided clinical study in patients with the appropriate genetic background to allow review by health regulatory agencies and to provide personalized therapy with dalcetrapib. It also offers great hope for precision treatments for patients with cardiovascular diseases and for curbing atherosclerosis, the first cause of mortality in the world. "

This discovery may pave the way for a new era in cardiovascular medicine, with personalized or precision drugs. The study appears in the Journal Circulation Cardiovascular Genetics.

Source: Medindia